Learn About Heterozygous Familial Hypercholesterolemia (HeFH)

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Heterozygous Familial Hypercholesterolemia (HeFH) Local Doctors?
Learn about our expert tiers
Learn more
What are the Latest Advances for Heterozygous Familial Hypercholesterolemia (HeFH)?
Lipoprotein apheresis in patients with familial hypercholesterolemia: a single center research.
Inclisiran: Small Interfering Ribonucleic Acid Injectable for the Treatment of Hyperlipidemia.
Tired of the same old research?
Check Latest Advances
Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis.
What are the latest Heterozygous Familial Hypercholesterolemia (HeFH) Clinical Trials?
Long-term Characterization of Lipoprotein Apheresis Technologies for Individual Device Adaption (LOLIDA)

Summary: Lipoprotein apheresis is often applied as the final treatment of patient with severe and medication resistant dyslipidemia and progressive atherosclerosis. The high effectiveness of lipoprotein apheresis to improve the patient's metabolic situation and thereby strongly minimize the incidence of cardiovascular events was confirmed by a variety of studies. While in the past years, mostly patients wi...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10mg Obicetrapib in Participants With HeFH and/or ASCVD Who Are Not Adequately Controlled by Their Lipid Modifying Therapies

Summary: This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to diet and maximally tolerated lipid-lowering therapy